Meeting
2019 Genitourinary Cancers Symposium
Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
Authors
Jeremie Calais
University of California Los Angeles, Los Angeles, CA
Jeremie Calais , Johannes Czernin , Wolfgang P Fendler , David Elashoff , Nicholas George Nickols
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT03582774
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS136)
DOI
10.1200/JCO.2019.37.7_suppl.TPS136
Abstract #
TPS136
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
![Randomized prospective phase 3 trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].](https://d201v5jt9ylckg.cloudfront.net/239/13724/178070/178070_poster_pv.jpg)
Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
First Author: Jeremie Calais
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk of biochemical recurrence (BCR) after radical prostatectomy (RP) in the ongoing phase 3 PRIMORDIUM study.
First Author: Boris A. Hadaschik
Poster
2023 ASCO Genitourinary Cancers Symposium
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.
First Author: Samuel Tremblay
Poster
2022 ASCO Annual Meeting
![Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774].](https://d201v5jt9ylckg.cloudfront.net/288/14370/211847/211847_A3419_poster_pv.jpg)
Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774].
First Author: Wesley R Armstrong